Elicio Therapeutics, Inc. (ELTX)
NASDAQ: ELTX · IEX Real-Time Price · USD
3.390
-0.390 (-10.32%)
At close: Jul 2, 2024, 4:00 PM
3.580
+0.190 (5.60%)
After-hours: Jul 2, 2024, 5:20 PM EDT
Elicio Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
32
Market Cap
34.82M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 0 | - | - |
| Dec 31, 2022 | 0 | - | - |
| Dec 31, 2021 | 28.31M | 25.43M | 883.06% |
| Dec 31, 2020 | 2.88M | 1.39M | 93.68% |
| Dec 31, 2019 | 1.49M | -2.54M | -63.09% |
| Dec 31, 2018 | 4.03M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Augmedix | 48.70M |
| Atara Biotherapeutics | 34.70M |
| electroCore | 18.69M |
| Curis | 9.81M |
| Lucid Diagnostics | 2.98M |
| vTv Therapeutics | 1.00M |
ELTX News
- 5 days ago - Elicio Therapeutics Announces Proposed Public Offering - GlobeNewsWire
- 5 days ago - Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P - GlobeNewsWire
- 14 days ago - Elicio Therapeutics Reports Inducement Grants - GlobeNewsWire
- 5 weeks ago - Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting - GlobeNewsWire
- 6 weeks ago - Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 2 months ago - Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting - GlobeNewsWire
- 3 months ago - Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting - GlobeNewsWire
- 3 months ago - Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates - GlobeNewsWire